Document Detail

Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents.
MedLine Citation:
PMID:  17470699     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The association between concentrations of uric acid and the metabolic syndrome in children and adolescents remains incompletely understood. The objective of this study was to examine how these 2 were associated in a nationally representative sample of US children and adolescents. METHODS AND RESULTS: We performed a cross-sectional analysis of 1370 males and females aged 12 to 17 years using data from the National Health and Nutrition Examination Survey 1999-2002. The prevalence of the metabolic syndrome was < 1% among participants in the lowest quartile of serum concentration of uric acid, 3.7% in the second quartile, 10.3% in the third quartile, and 21.1% in the highest quartile. Compared with the lowest 2 quartiles of uric acid together (< or = 291.5 micromol/L), the odds ratios were 5.80 (95% confidence interval, 3.22 to 10.46) for those in the third quartile (> 291.5 to < or = 339 micromol/L or > 4.9 to < or = 5.7 mg/dL) and 14.79 (95% confidence interval, 7.78 to 28.11) for those in the top quartile (> 339 micromol/L) after adjustment for age, sex, race or ethnicity, and concentrations of C-reactive protein. Starting with the lowest quartile of concentration of uric acid, mean concentrations of serum insulin were 66.2, 66.7, 79.9, and 90.9 pmol/L for ascending quartiles, respectively (P for trend <0.001). CONCLUSIONS: Among US children and adolescents, serum concentrations of uric acid are strongly associated with the prevalence of the metabolic syndrome and several of its components.
Earl S Ford; Chaoyang Li; Stephen Cook; Hyon K Choi
Related Documents :
16602719 - Influence of peg endgroup and molecular weight on its reactivity for lipase-catalyzed p...
1619189 - Changes in serum and urinary uric acid levels in normal human subjects fed purine-rich ...
5823049 - Social class gradients and serum uric acid in males and females.
10596359 - Formulation development of allopurinol suppositories and injectables.
4979099 - Degradation of uric acid by certain aerobic bacteria.
15792819 - Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis pati...
20471829 - Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1h-indol-7-yl]carbonyl)amino]cyclopr...
6820329 - Production of kojic acid by resuspended mycelia of aspergillus flavus.
12588949 - Covalent binding of hydroxy-alkenals 4-hdde, 4-hhe, and 4-hne to ethanolamine phospholi...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2007-04-30
Journal Detail:
Title:  Circulation     Volume:  115     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-05-15     Completed Date:  2007-06-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2526-32     Citation Subset:  AIM; IM    
Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy, MS K66, Atlanta, GA 30341, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Area Under Curve
Biological Markers
Blood Glucose / analysis
Blood Pressure
C-Reactive Protein / analysis
Cholesterol, HDL / blood
Cross-Sectional Studies
Ethnic Groups / statistics & numerical data
Insulin / blood
Kidney / metabolism
Metabolic Syndrome X / blood*,  epidemiology
Predictive Value of Tests
ROC Curve
Triglycerides / blood
United States / epidemiology
Uric Acid / blood*
Reg. No./Substance:
0/Biological Markers; 0/Blood Glucose; 0/Cholesterol, HDL; 0/Triglycerides; 11061-68-0/Insulin; 69-93-2/Uric Acid; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-...
Next Document:  Clinical end points in coronary stent trials: a case for standardized definitions.